Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nova Mentis Life Science Corp. (C:NOVA)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for NOVA within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 12, 2022 07:30 ET
Nova Mentis Provides Corporate Update - 2022 Planned Catalysts
VANCOUVER, BC, Jan. 12, 2022 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders reviews its 2021 drug development accomplishments and its planned 2022 steps towards drug approval and commercialization.
Read full article
Dec 31, 2021 07:30 ET
Nova Mentis Welcomes New CFO Rebecca Hudson
VANCOUVER, BC, Dec. 31, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce Rebecca Hudson has joined NOVA as its Chief Financial Officer, adding corporate finance, accounting and risk management experience to the Company's management team.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.70
--
--
Price to Sales - TTM
4,372.67
23.88
10.69
Price to Book - most recent quarter
2.45
2.87
2.52
Price to Cash Flow per share - TTM
--
17.69
13.73
Price to Free Cash Flow per share - TTM
--
38.57
28.71
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 202176,43625,460
Dec 15, 202150,97619,457
Nov 30, 202131,51912,909
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Nova Mentis Life Science Corp. is a Canada-based biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company operates in two segments: development of cannabis products and research and development of psilocybin in Canada through the Company's subsidiaries, Nova Mentis Biotech Corp. and Pilz Bioscience Corp. Nova Mentis Biotech Corp. and Pilz Bioscience Corp. is engaged in psilocybin research and development. Nova Mentis Biotech Corp. is engaged in the development of psilocybin-based therapeutics and diagnostics for neuroinflammatory disorders. It is focused indications are obesity, diabetes, liver disease. Pilz Bioscience Corp. (Pilz) is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD).

See business summary

 

Twitter

Search (past week) for $NOVA.CA

  • No tweets found